Pressmeddelanden från Cessatech

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Cessatech convenes its Annual General Meeting 27 feb 08:30

Cessatech A/S Announces Financial Results for the Full Year 2025 02 feb 08:00

Welcome to the first quarter of 2026 13 nov 2025 08:30

Third Quarter Report Q3-2025 31 okt 2025 13:00

CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children 21 aug 2025 08:30

Second Quarter Report Q2-2025 14 aug 2025 18:00

The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children 27 jun 2025 13:31

Cessatech Q&A – June company presentation 19 jun 2025 13:30

Cessatech strengthens Executive Management with the promotion of Martin Juhl 11 jun 2025 14:15

Cessatech announce completion of the directed issue of shares 28 maj 2025 22:30

Cessatech has carried out a directed share issue of approximately DKK 14.8 million to strengthen its financial position ahead of U.S. commercial launch 28 maj 2025 17:30

Cessatech announces intention to carry out a directed share issue ahead of U.S. commercial launch 28 maj 2025 17:15

Cessatech announces positive top-line results from its final CT001 Study 0202 15 maj 2025 08:30

First Quarter Report Q1-2025 30 apr 2025 15:45

Cessatech announces that recruitment has completed in the Paediatric Study 0202, and now the EMA submission process can be initiated for CT001 28 mar 2025 11:30

Minutes from the Annual General Meeting in Cessatech A/S 12 mar 2025 08:30

Annual General Meeting - 28 March 2025 28 feb 2025 08:30

Cessatech A/S publishes Annual Report for the fiscal year 2024 04 feb 2025 11:30

Cessatech receives positive Notified Body opinion under MDR for CT001 23 dec 2024 12:00

Cessatech updates the milestones for the coming year 13 nov 2024 13:00

Third Quarter Report Q3-2024 16 okt 2024 10:00

Cessatech announces that recruitment has today reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202 02 sep 2024 10:00

Cessatech and Proveca partnership - Q&A 26 aug 2024 08:30

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001 21 aug 2024 08:30

Second Quarter Report Q2-2024 12 aug 2024 11:50

Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the forthcoming US launch of its lead program CT001 02 aug 2024 15:00

Key Cessatech priorities for the rest of the year 26 jul 2024 16:00

Grant of incentive warrants to Employees, CEO and the Board of Directors 05 jul 2024 14:36

Cessatech announces changes to the Board of Directors 05 jul 2024 14:31

Minutes of the Extraordinary General Meeting – 5 July 2024 28 jun 2024 12:10

Cessatech presents new data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001 20 jun 2024 16:00

EXTRAORDINARY GENERAL MEETING 03 jun 2024 13:00

Cessatech announces superior simulated pain efficacy in children favouring its lead candidate CT001 relative to its active comparators.27 maj 2024 14:53

Cessatech reports first patient dosed in final Safety Study 0202 of lead product candidate CT001 15 maj 2024 08:45

First Quarter Report Q1-2024 27 mar 2024 11:00

Minutes from the Annual General Meeting in Cessatech A/S 11 mar 2024 17:00

Annual General Meeting - 27 March 2024 29 feb 2024 09:00

Cessatech A/S publishes Annual Report for the fiscal year 2023 30 jan 2024 08:30

CESSATECH ANNOUNCES RESULT OF WARRANT EXERCISE FOR WARRANTS OF SERIES TO2 23 jan 2024 17:41

Correction: LAST DAY OF TRADING IN WARRANTS OF SERIES TO2 IN CESSATECH IS TOMORROW, JANUARY 24, 2024 23 jan 2024 17:02

LAST DAY OF TRADING IN WARRANTS OF SERIES TO2 IN CESSATECH IS TOMORROW, JANUARY 24, 2024 22 jan 2024 08:30

CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO2 12 jan 2024 08:00

CESSATECH ANNOUNCES THE START OF THE EXERCISE PERIOD FOR WARRANTS OF SERIES TO2 11 jan 2024 08:00

CESSATECH ANNOUNCES TO2 WARRANT EXERCISE PRICE AND START OF EXERCISE PERIOD 04 jan 2024 17:30

Q&A session related topline data Study 0205 16 nov 2023 08:30

Third Quarter Report Q3-2023 25 okt 2023 08:00

Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children 21 sep 2023 13:55

Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001 12 sep 2023 08:45

Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children 24 aug 2023 17:30

Second quarter report Q2-2023 17 aug 2023 17:30

Cessatech secures DKK 5 million loan facility agreement to support the US launch of its lead program CT001 30 jun 2023 08:58

Cessatech - Ventis Pharma US partnership - Q&A 27 jun 2023 07:50

Cessatech and Ventis Pharma announce US partnership for CT001 31 maj 2023 08:30

Cessatech provides positive news regarding shelf life of CT001 12 maj 2023 08:00

First quarter report Q1-2023 19 apr 2023 10:43

April business update - the business strategy 23 mar 2023 14:00

Minutes from the Annual General Meeting in Cessatech A/S 23 mar 2023 14:00

Cessatech announces new Chairman of the Board 08 mar 2023 17:00

Annual General Meeting - 23 March 2023 28 feb 2023 16:30

Cessatech A/S publishes Annual Report for the fiscal year 2022 27 jan 2023 07:30

Welcome to 2023 and our January business update...17 jan 2023 17:30

Grant of incentive warrants to Employees, CEO and the Board of Directors 07 dec 2022 16:00

CESSATECH’S COMPENSATION ISSUE IN CONNECTION WITH THE RECENT RIGHTS ISSUE HAS BEEN REGISTERED 24 nov 2022 17:00

CESSATECH’S BOARD RESOLVES ON COMPENSATION ISSUE IN CONNECTION WITH THE RECENT RIGHTS ISSUE 18 nov 2022 16:45

CESSATECH ANNOUNCES LAST DAY OF TRADING IN BTU AND THE FIRST DAY OF TRADING IN WARRANTS OF SERIES TO2 18 nov 2022 08:30

Third quarter report Q3-2022 14 nov 2022 14:06

CESSATECH ANNOUNCES OUTCOME OF RIGHTS ISSUE 08 nov 2022 11:18

TOMORROW IS THE LAST DAY OF THE SUBSCRIPTION PERIOD IN CESSATECH’S RIGHTS ISSUE 04 nov 2022 10:21

Minutes of the Extraordinary general meeting 27 okt 2022 17:30

THE SUBSCRIPTION PERIOD HAS STARTED IN CESSATECH’S RIGHTS ISSUE 20 okt 2022 18:00

Extraordinary general meeting 20 okt 2022 08:30

Correction MAR-label: CESSATECH PUBLISHES OFFERING MEMORANDUM IN CONNECTION WITH 80% GUARANTEED RIGHTS ISSUE 19 okt 2022 18:00

CESSATECH ANNOUNCES DKK 18.3 MILLION CAPITAL RAISE THROUGH A 80% GUARANTEED RIGHTS ISSUE TO FINANCE PIVOTAL DEVELOPMENT OF CT001 10 okt 2022 17:00

Great progress during Q3 – more to come 23 sep 2022 08:30

Cessatech reports successful outcome of pharmacokinetic trial in children of lead candidate 05 sep 2022 17:30

Cessatech reports first patient dosed in pivotal trial of lead product candidate 19 aug 2022 08:30

Second quarter report Q2-2022 – green light for the pivotal trial 0205 11 aug 2022 08:30

Good things are worth waiting for - welcome to the second half of 2022!30 jun 2022 17:00

Cessatech reports Regulatory Green Light for trial 0205, the pivotal trial for CT001 - first patient expected shortly 16 maj 2022 08:15

Cessatech reports last patient dosed in pharmacokinetic trial in children of lead candidate 19 apr 2022 17:30

First quarter report Q1-2022 - preparing for the pivotal trial 31 mar 2022 09:00

Newsletter #6 - Mar 2022 17 mar 2022 16:30

Minutes from the Annual General Meeting in Cessatech A/S 08 mar 2022 08:30

Cessatech reports successful outcome of bioavailability trial 0204 with CT001 03 mar 2022 08:45

Cessatech A/S publishes annual report for the fiscal year 2021 02 mar 2022 09:00

Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the annual general meeting to be held on 17 March 2022.24 feb 2022 08:00

Fourth quarter report Q4-2021 - preparing for the pivotal trial 22 feb 2022 08:58

Cessatech expects to report on its bioavailability trial 0204 within a few weeks 06 jan 2022 08:00

Cessatech announces changes to the Board of Directors 04 jan 2022 17:00

Cessatech’s warrant exercise registered with the Danish Companies Registration Office 30 dec 2021 16:00

Newsletter update #5 - Dec 2021 22 dec 2021 13:07

Cessatech successfully raises approx. DKK 24.3 million through warrant exercise and does not activate guarantee commitments 14 dec 2021 08:00

Last day of trading in Cessatech’s warrants of series TO 1 is today Tuesday 14 December 2021 08 dec 2021 08:00

CEO and Board of Directors have exercised warrants of series TO 1 25 nov 2021 08:07

The exercise period for warrants of series TO 1 begins today 19 nov 2021 08:00

Third quarter report Q3-2021 - focusing on next trial (0205)12 nov 2021 17:30

Newsletter #4 - Nov 2021, Preparing for next year...02 nov 2021 18:00

Cessatech annonces the issuance of its first US patent covering CT001 20 aug 2021 08:00

Cessatech reports first patient dosed in pharmacokinetic trial in children of lead product candidate 19 aug 2021 08:00

Second quarter report Q2-2021 - planning for the pivotal trials